Assenagon Asset Management
ORMP icon

Assenagon Asset Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Assenagon Asset Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,118
Closed -$32K – 1421
2024
Q3 		$32K Sell
13,118
-3,301
-20% -$8.05K ﹤0.01% 1355
2024
Q2 		$42.2K Sell
16,419
-2,240
-12% -$5.32K ﹤0.01% 1397
2024
Q1 		$54.5K Buy
+18,659
New +$52.2K ﹤0.01% 1349
2022
Q2 		– Sell
-385,413
Closed -$3.33M – 1555
2022
Q1 		$3.33M Buy
+385,413
New +$3.95M 0.01% 657

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Assenagon Asset Management's ORMP Position: Q4 2024 in Review

Assenagon Asset Management sold out of Oramed Pharmaceuticals (ORMP) in Q4 2024, closing a stake of 13,118 shares — an estimated $32K sold.

Assenagon Asset Management first reported a position in ORMP in Q1 2022 and held it in 4 quarters. The position peaked at $3.33M in Q1 2022. 56 funds tracked by Wall St. Rank hold ORMP as of Q4 2024.

  • Assenagon Asset Management reported no remaining Oramed Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Assenagon Asset Management sold 13,118 Oramed Pharmaceuticals shares in Q4 2024, an estimated $32K.
  • Assenagon Asset Management first reported a position in Oramed Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Assenagon Asset Management's Oramed Pharmaceuticals position peaked at $3.33M in Q1 2022.
  • 56 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2024.

Based on Assenagon Asset Management's 13F filing for Q4 2024, filed 14 Jan 2025.